Chief Executive Officer & President
Patrick Fourteau served as President and Chief Executive Officer of Shionogi US operations, from 2008 until 2010 following the acquisition of Sciele by Shionogi & Co., LTD. in 2008, Mr. Fourteau served as President, CEO, member of the board of directors of Sciele Pharma, Inc. from 2003 until 2008. Mr. Fourteau served as President of the US sales operations of inVentiv Health, Inc. from 2000 to 2002, President of various divisions of St. Jude Medical, Inc. from 1995 to 2000 and as an Executive of Eli Lilly and Company. He serves on the Board of Insys Therapeutics, Inc. Mr. Fourteau earned his B.A. and M.A. in Mathematics from the University of California, Berkeley and an MBA from Harvard University.
Harry H. Penner, Jr.
Executive Chairman, Founder
Mr. Penner has been a founder of seven other biotechnology companies, among which are Rib-X Pharmaceuticals (now Melinta Therapeutics), Prevention Pharmaceuticals, Affinimark Technologies, and Marinus Pharmaceuticals. From 1993 to 2001, he was President and Chief Executive Officer of Neurogen Corporation. Previously, he served as Executive Vice President of Novo Nordisk A/S and President of Novo Nordisk of North America, Inc. from 1988 to 1993. From 1985 to 1988, he was Executive Vice President and General Counsel of Novo Nordisk A/S. Mr. Penner, who also serves on the board of Celldex Therapeutics (CLDX), earned a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. from New York University.
Larry Dillaha, M.D.
Executive Vice President Operations
Prior to joining our company, Larry Dillaha, M.D. has served as the Chief Medical Officer at Insys Therapeutics, Inc. from April 2010 until May 2014. From 2006 until 2010, Dr. Dillaha served as EVP and Chief Medical Officer for Shionogi and Co., Ltd. (formerly Sciele Pharma, Inc.). While at Sciele, Dr. Dillaha oversaw the development and successful NDA approvals of 2 cardiology products, SULAR low dose, a LifeCycle extension of SULAR, and TRIGLIDE a fenofibrate. He has extensive experience in planning and overseeing clinical development programs. Dr. Dillaha served as Medical Director for Sanofi-Aventis. Dr. Dillaha earned his M.D. degree as well as a B.A. in Biology from the University of Tennessee.
Jeff Patrick, Pharm.D.
Chief Scientific Officer
Dr. Patrick has over fifteen years of scientific and medical experience in the pharmaceutical industry. Dr. Patrick has held a variety of leadership roles at Myogen, Gilead Sciences, Dyax and Mallinckrodt.
At Mallinckrodt, Jeff served as the Global Vice President, Medical Affairs, where he helped Mallinckrodt transition into a fully integrated specialty pharmaceutical company including assimilating a series of business acquisitions, including CNS Therapeutics, Cadence and Questcor.
Jeff holds a Doctorate of Pharmacy from the University of Tennessee Health Science Center, and completed a Specialty Residency in Ambulatory Care at the University of Tennessee Medical Center, Knoxville.
Chief Business Officer
Mr. Richardson has over twenty years of experience in pharmaceutical Marketing, Sales, Product Planning, Business Development and Licensing. Mr. Richardson had a variety of leadership roles at Grünenthal, Aton, Cephalon, Johnson & Johnson, and Merck. At Grünenthal, Michael served as Head of Commercial Affairs. At Aton Pharma, Michael served as Vice-President of Commercial Operations. At Cephalon, Michael served as Group Product Director resulting in the successful launch of multiple products. Michael holds a BA degree in Chemistry from West Virginia University and a MBA from the Fuqua School of Business at Duke University.
Chief Financial Officer
Prior to joining New Haven Pharmaceuticals, Michael Milligan served as the Chief Accounting Officer at Shionogi, Inc. from October 2008 until November 2014 where he was responsible for accounting, financial reporting, internal controls, tax, payroll and risk management. Prior to Shionogi, Mr. Milligan served in multiple accounting and finance positions at Sciele, Inc. culminating as Vice-President Finance. Prior to Sciele, Mr. Milligan worked for Ernst & Young and KPMG in their assurance practices concentrating on manufacturing, retail and distribution SEC clients. Mr. Milligan earned his M.B.A. from Georgia State University as well as a B.B.A. in Accounting from the University of Miami.
Chief Information Officer
Kimberly has nearly 20 years of experience in the pharmaceutical industry, with 7 years of service as a member of information technology senior management. She has served in a variety of technology disciplines, including development, applications, and relationship management. Most recently, Kimberly was Director of Business Engagement at Alexion Pharmaceuticals. As a direct report to the CIO, she led the global Business Analysis, Application Administration, and Development teams. While there, she led several large-scale, multi-million dollar initiatives, including CRM and document management system implementations. Prior to Alexion, Kimberly held technology positions at Purdue Pharma in sales systems, web technology, and development.
Kimberly earned her Bachelor of Arts from the Binghamton University and her Master of Arts from Southern Connecticut State University.
Mr. Edwards comes to our company with over 35 years of experience working in the pharmaceutical and biopharmaceutical research & development areas. Prior to joining our company he was at Alexion Pharmaceuticals from 2004 to 2009, leaving with title of Executive Director of Global Regulatory Operations and US Regulatory Affairs.
In addition, Mr. Edwards worked for Purdue Pharma L.P. as the Director of Worldwide Regulatory Operations and prior to that Mr. Edwards was with Bayer Pharmaceuticals Inc. for 18 years starting in the CNS Medical Research group and advancing to the position of Head of Global Regulatory Submissions before leaving in 2003.
Mr. Edwards professional career also includes time at Serono Laboratories, Inc. USA, as a Senior Pharmaceutical Research Associate responsible for overseeing the monitoring of all Interferon [both natural & recombinant (r.DNA)] phase I & II clinical programs. Mr. Edwards also worked for the Procter & Gamble organization for 15 years where he started working in Toxicology advancing into Clinical Research, where he was a Medical Research Associate responsible for monitoring CNS and Anti-Infective clinical studies in North America and Mexico.
Mr. Edwards earned his Bachelor of Professional Science degree in Scientific Design and Financial Management from the State University of New York.
Andy Pennell, Pharm.D.
Vice President Medical Affairs
Andy has over 21 years of medical affairs experience in the pharmaceutical and medical device industries. He has held a variety of leadership roles at Bristol-Myers Squibb, Boston Scientific, King Pharmaceuticals, Archimedes Pharma, and Mallinckrodt. Most recently, Andy was a Director with the Medical Science Liaisons at Mallinckrodt. He helped build, develop and train the field medical team for support of new product launches. He worked closely across Medical and Commercial functional teams to deliver fully aligned medical support for the Specialty Pharmaceuticals division.
Andy earned his Doctorate and Bachelor of Science in Pharmacy from the University of Georgia, a B.A. in Biology from LaGrange College, and completed a two year Residency at the University of Kentucky Medical Center in Lexington.
Vice President Clinical Operations
Sang has over twenty years of clinical research experience in the pharmaceutical and medical device industries. Before joining our company, Sang held a variety of leadership roles as the Portfolio Lead, Senior Director Clinical Operations, Director Clinical Operations, Director Clinical Project Management, Associate Director Clinical Studies. During her past tenures at InVasc Therapeutics, Shionogi and Co. LTD. (formerly Sciele Pharma, Inc.), Altea Therapeutics, Emory University, as well as at various CROs, Sang demonstrated strong leadership in leading cross-functional global clinical projects in multiple therapeutic areas.
Sang earned her Bachelor of Science from Dai Hoc Y Duoc (University of Medicine & Pharmacy) in Vietnam, and received her Master in Business Management from Tulane University. She is also a Certified Project Management Professional (PMP) in the pharmaceutical industry by PMI, and a Certified Clinical Research Coordinator (CCRC) by ACRP.
Vice President Quality Assurance
Cheryl Nash serves as the Director of Quality Assurance at NHP since June 2013. Prior to joining our company, she served as Director Contractor QA from 2011 to May 2013 and Director QA Contract Manufacturing from 2009 to 2011 for Alexion Pharmaceuticals, Inc. While at Alexion, Cheryl directed the selection, qualification and oversight of contract manufacturers for biologic products and small molecules. She also oversaw the development and implementation of a PAI education program and inspection procedures that led to the successful PAI and approval for Alexion's first commercial product Soliris™.
Ms. Nash earned her B.S. degree in Microbiology from The Ohio State University.